Clara Depommier

TL;DR: It is shown that A. muciniphila retains its efficacy when grown on a synthetic medium compatible with human administration and enhanced its capacity to reduce fat mass development, insulin resistance and dyslipidemia in mice, and Amuc_1100, a specific protein isolated from the outer membrane of A. Sydneyi, interacts with Toll-like receptor 2, is stable at temperatures used for pasteurization and partly recapitulates the beneficial effects of the bacterium.

TL;DR: In this article, Akkermansia muciniphila, a gut microbe previously associated with metabolic health in preclinical models, is safe and well tolerated in humans and may improve metabolic parameters in overweight and obese patients.

TL;DR: A large body of evidence is presented supporting the concept that gut microbiota-based therapies can be used to modulate host metabolism, and the authors expect to see such approaches moving from bench to bedside in the near future.

TL;DR: The effects of pasteurized A. muciniphila on whole-body energy metabolism during high-fat diet feeding is investigated by using metabolic chambers and it is found that energy expenditure was enhanced independently from changes in markers of thermogenesis or beiging of the white adipose tissue.

TL;DR: This Review covers the discovery of Akkermansia muciniphila and its association with health and disease, including metabolic diseases, and summarizes the numerous findings and main mechanisms of action by which this intestinal symbiont improves health.